June 2021
Volume 62, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2021
Recurrence Rate of Cystoid Macular Edema with Topical Dorzolamide Treatment and its Risk Factors in Retinitis Pigmentosa
Shotaro Shimokawa; Yusuke Murakami; Kohta Fujiwara; Jun Funatsu; Shunji Nakatake; Yoshito Koyanagi; Masato Akiyama; Noriko Yoshida; Atsunobu Takeda; Yasuhiro Ikeda; Koh-hei Sonoda
Author Affiliations & Notes
  • Shotaro Shimokawa
    Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Fukuoka, Japan
  • Yusuke Murakami
    Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Fukuoka, Japan
  • Kohta Fujiwara
    Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Fukuoka, Japan
  • Jun Funatsu
    Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Fukuoka, Japan
  • Shunji Nakatake
    Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Fukuoka, Japan
    Ophthalmology, Faculty of Medicine, University of Oita, Yufu, Oita, Japan
  • Yoshito Koyanagi
    Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Fukuoka, Japan
  • Masato Akiyama
    Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Fukuoka, Japan
    Ocular Pathology and Imaging Science,, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Fukuoka, Japan
  • Noriko Yoshida
    Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Fukuoka, Japan
    Ophthalmology, Fukuoka Dental College, Fukuoka, Fukuoka, Japan
  • Atsunobu Takeda
    Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Fukuoka, Japan
  • Yasuhiro Ikeda
    Ophthalmology, Faculty of Medicine, University of Miyazaki, Miyazaki, MIyazaki, Japan
  • Koh-hei Sonoda
    Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Fukuoka, Japan
  • Footnotes
    Commercial Relationships   Shotaro Shimokawa, None; Yusuke Murakami, None; Kohta Fujiwara, None; Jun Funatsu, None; Shunji Nakatake, None; Yoshito Koyanagi, None; Masato Akiyama, None; Noriko Yoshida, None; Atsunobu Takeda, None; Yasuhiro Ikeda, None; Koh-hei Sonoda, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2021, Vol.62, 3287. doi:
  • Views
  • Share
  • Tools
    • Alerts
      User Alerts
      You are adding an alert for:
      Recurrence Rate of Cystoid Macular Edema with Topical Dorzolamide Treatment and its Risk Factors in Retinitis Pigmentosa
      You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
      The alert will be sent to:
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation
      Citation

      Shotaro Shimokawa, Yusuke Murakami, Kohta Fujiwara, Jun Funatsu, Shunji Nakatake, Yoshito Koyanagi, Masato Akiyama, Noriko Yoshida, Atsunobu Takeda, Yasuhiro Ikeda, Koh-hei Sonoda; Recurrence Rate of Cystoid Macular Edema with Topical Dorzolamide Treatment and its Risk Factors in Retinitis Pigmentosa. Invest. Ophthalmol. Vis. Sci. 2021;62(8):3287.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

      ×
    • Get Permissions
  • Supplements
Abstract

Purpose : We previously reported that topical treatment with 1.0% topical dorzolamide was effective in 59.1% patients with cystoid macular edema secondary to retinitis pigmentosa (RP-CME). However, the rate of RP-CME recurrence during follow-up have not been fully characterized. The purpose of this study is to investigate the recurrence rate of RP-CME after an initiation of topical dorzolamide and its risk factors.

Methods : We retrospectively reviewed the data of RP patients who was diagnosed as having RP-CME and treated with topical 1.0% dorzolamide 3 times a day from the electronic medical records. Patients who showed a treatment response to topical 1.0% dorzolamide, defined as the resolution of foveal cysts or >20% reduction of central subfield thickness (CST) from baseline in optical coherence tomography (OCT), were included in this study. The day of treatment initiation was set as the baseline and topical dorzolamide treatment was continued during follow-up. At each follow-up visit, the recurrence of RP-CME (defined as a reappearance of foveal cyst; >20% increase in CST compared to previous visit; or CST exceeding baseline) was evaluated. Risk factors for the recurrence were analyzed by Cox proportional hazards modeling. Kaplan-Meier survival analysis was used to evaluate the time to recurrent RP-CME.

Results : 40 RP-CME patients showed a treatment response to topical 1.0% dorzolamide.
During the mean 3.9-yr follow-up, 21 patients showed recurrent RP-CME. The recurrence rate of RP-CME was 20.2% at 1 year increasing to 46.3% and 57.8% at 3 and 5 years, respectively. High baseline central subfield thickness was significantly associated with recurrent RP-CME (hazard ratio [HR], 1.09 per 10 µm increase; 95%CI, 1.03–1.14; p=0.001).

Conclusions : The recurrence rate of RP-CME increases during the follow-up periods. High baseline CST was a risk factor of recurrent RP-CME.

This is a 2021 ARVO Annual Meeting abstract.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Attribution-NonCommercial-NoDerivatives
Copyright © 2025 Association for Research in Vision and Ophthalmology.
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept